Aerie Pharmaceuticals, Inc. (AERI)

$15.12

-0.02 (-0.13%)
Rating:
Recommendation:
Buy
Symbol AERI
Price $15.12
Beta -0.055
Volume Avg. 1.50M
Market Cap 747.120M
Shares () -
52 Week Range 4.81-15.37
1y Target Est -
DCF Unlevered AERI DCF ->
DCF Levered AERI LDCF ->
ROE 55.36% Strong Buy
ROA -12.83% Sell
Operating Margin -
Debt / Equity -373.03% Strong Sell
P/E -
P/B -5.10 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AERI news


Dr. Vicente Anido
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.